PEDIATRICS Vol. 78 No. 4 October 1986, pp. 728-735
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Preblud, S. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Preblud, S. R.

Varicella: Complications and Costs

Stephen R. Preblud MD1

1 From the Division of Immunization, Center for Prevention Services, Centers for Disease Control, Public Health Service, US Department of Health and Human Services, Atlanta

Vanicella (chickenpox) has long been considered a benign, inevitable disease of childhood. Complications are generally mild and rarely severe, and virtually every individual is infected by adulthood. Infection is associated, however, with a high risk of serious complications in certain high-risk groups, such as leukemic children. Concerns about the severity of varicella in this population have led to the development and testing of a live, attenuated vaccine. Because of the favorable results thus far available, the vaccine may soon be licensed for use in high-risk individuals. The fact that a vaccine may soon be available has led to an increased interest in the potential benefits of a childhood varicella vaccine program. The costs associated with varicella infection in normal persons without a varicella vaccination program have been estimated to be approximately $400 million, 95% of which is the cost of caring for a child at home. Vaccination of normal 15-month-old children with a safe and effective vaccine with long-lasting immunity could reduce the cost by 66% and result in a savings of $7 for every dollar spent on the vaccination program. This assumes that vaccine would be administered only once with measles, mumps, and rubella vaccine, that there would be no increase in the number of varicella cases in older persons who are at increased risk for complications, and that there would be no deleterious effect on the occurrence and severity of herpes zoster. If the assumptions cited above hold true, then it would appear that normal children would benefit from prevention of varicella by vaccination, not by virtue of the severity of the disease but rather because of the inevitability of the disease and its associated expense.




This article has been cited by other articles:


Home page
 PediatricsHome page
C. Ziebold, R. von Kries, R. Lang, J. Weigl, and H. J. Schmitt
Severe Complications of Varicella in Previously Healthy Children in Germany: A 1-Year Survey
Pediatrics, November 1, 2001; 108(5): e79 - 79.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
J Breuer
Vaccination to prevent varicella and shingles
J. Clin. Pathol., October 1, 2001; 54(10): 743 - 747.
[Abstract] [Full Text] [PDF]

Home page
 Arch. Dis. Child.Home page
S A Skull and E E L Wang
Current topic: Varicella vaccination{---}a critical review of the evidence
Arch. Dis. Child., August 1, 2001; 85(2): 83 - 90.
[Full Text] [PDF]

Home page
 Clin. Microbiol. Rev.Home page
C. Aitken and D. J. Jeffries
Nosocomial Spread of Viral Disease
Clin. Microbiol. Rev., July 1, 2001; 14(3): 528 - 546.
[Abstract] [Full Text] [PDF]

Home page
 CMAJHome page
Varicella vaccination: Recommendation statement from the Canadian Task Force on Preventive Health Care
Can. Med. Assoc. J., June 26, 2001; 164(13): 1888 - 1889.
[Full Text] [PDF]

Home page
 PediatricsHome page
B. Law, C. Fitzsimon, L. Ford-Jones, N. MacDonald, P. Déry, W. Vaudry, E. Mills, S. Halperin, A. Michaliszyn, and M. Rivière
Cost of Chickenpox in Canada: Part I. Cost of Uncomplicated Cases
Pediatrics, July 1, 1999; 104(1): 1 - 6.
[Abstract] [Full Text]

Home page
 PediatricsHome page
B. Law, C. Fitzsimon, L. Ford-Jones, J. McCormick, and M. Rivière
Cost of Chickenpox in Canada: Part II. Cost of Complicated Cases and Total Economic Impact
Pediatrics, July 1, 1999; 104(1): 7 - 14.
[Abstract] [Full Text]

Home page
 Arch. Dis. Child.Home page
A Jaeggi, R P Zurbruegg, and C Aebi
Complications of varicella in a defined central European population
Arch. Dis. Child., December 1, 1998; 79(6): 472 - 477.
[Abstract] [Full Text]

Home page
 JBJSHome page
P. SCHRECK, P. SCHRECK, J. BRADLEY, and H. CHAMBERS
Musculoskeletal Complications of Varicella
J. Bone Joint Surg. Am., November 1, 1996; 78(11): 1713 - 9.
[Abstract] [Full Text]